LS-102
Modify Date: 2024-01-08 02:04:04
LS-102 structure
|
Common Name | LS-102 | ||
|---|---|---|---|---|
| CAS Number | 1456891-34-1 | Molecular Weight | 452.60 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H36N8O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LS-102LS-102 is a selective synoviolin inhibitor (Syvn1). LS-102 inhibits the autoubiquitination of synoviolin with an IC50 of ~15 μM. LS-102 has the potential for rheumatoid arthritis treatment[1][2]. |
| Name | LS-102 |
|---|
| Description | LS-102 is a selective synoviolin inhibitor (Syvn1). LS-102 inhibits the autoubiquitination of synoviolin with an IC50 of ~15 μM. LS-102 has the potential for rheumatoid arthritis treatment[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | LS-102 inhibits proliferation of RSCs with an IC50 of 5.4 µM[1]. LS-102 suppresses proliferation of rheumatoid synovial cells (RSCs) in a Syvn1-dependent manner. LS-102 suppresses polyubiquitination of target proteins of Syvn1, including nuclear factor erythroid 2-related factor 2 (NRF2), V247M α-sarcoglycan mutant, and PGC-1β. LS-102 inhibits E3 ligase activity of Synoviolin (Syvn1)[2]. Cell Viability Assay[1] Cell Line: Rheumatoid synovial cells (RSCs) Concentration: 20, 40, 60 μM Incubation Time: 12 hours Result: Inhibited proliferation of RSCs with an IC50 of 5.4 µM. |
| In Vivo | LS-102 (1.3-4 mg/kg; i.p.; daily for 4 weeks) reduces clinical severity scores in a CIA model[1]. Animal Model: 7-week-old DBA/1 male mice (CIA model)[1] Dosage: 1.3, 4.0 mg/kg Administration: I.p.; daily for 4 weeks Result: Reduced the clinical severity scores. |
| References |
| Molecular Formula | C24H36N8O |
|---|---|
| Molecular Weight | 452.60 |